<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>290</id>
    <completedYear>2013</completedYear>
    <publishedYear>2013</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>27</pageFirst>
    <pageLast>32</pageLast>
    <pageNumber/>
    <edition/>
    <issue>1</issue>
    <volume>1</volume>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">CSR boundaries in the pharmaceutical industry: Is outsourcing of clinical trials to developing countries really unethical?</title>
    <abstract language="eng">Does life have a different price according to the country where people are born? Should there be a customized definition of ethics in function of the country where clinical trials are being carried on? The actual international regulatory environment proves to be inadequate to guarantee a fair treatment of patients involved in drug trials around the world, a situation which is proven by the case of India. The incapacity of Indian national regulators to efficiently monitor trials and enforce the law, as well as the increasing use of outsourcing in clinical trials gives place to abuse of patients’ rights in the name of science or for corporate profits. The article aspires to make a modest contribution to this field by analyzing to what extent pharmaceutical companies are interested in perpetuating the diffuse area around the responsibility and ethics of drug trials in developing countries. Moreover, it offers suggestions as to how they can improve their CSR practices.</abstract>
    <parentTitle language="eng">Journal of European Management &amp; Public Affairs Studies</parentTitle>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-2903</identifier>
    <identifier type="issn">2199-1618</identifier>
    <identifier type="doi">10.15771/2199-1618_2013_1_1_5</identifier>
    <enrichment key="review.accepted_by">2</enrichment>
    <licence>Creative Commons - CC BY 3.0 DE - Namensnennung 3.0 Deutschland</licence>
    <author>Alexandra Theodora Gaidos</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>bioethics</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>clinical trial</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>contract research organization</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>drug trial</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>ethics</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>outsourcing</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>pharmaceutical industry</value>
    </subject>
    <collection role="ddc" number="330">Wirtschaft</collection>
    <collection role="institutes" number="">Fachbereich Betriebswirtschaft / Wirtschaftsinformatik (bis 8/2014)</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="green_open_access" number="3">Diamond Open Access</collection>
    <collection role="Kollektionen" number="">Journal of European management &amp; public affairs studies</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-th-wildau/files/290/5-71-1-PB.pdf</file>
  </doc>
</export-example>
